Preliminary clinical observations of low-dose radiotherapy for eight cases of severe/critical COVID-19
Objective To investigate the efficacy and adverse reactions of whole-lung low-dose radiotherapy(LDRT)in patients with severe/critical coronavirus disease 2019(COVID-19).Methods Eight patients with severe/critical COVID-19 treated in the Jiangyin Hospital Affiliated to Nantong University from January to June 2023 who were treated with whole-lung LDRT after deteriorating or failing to improve post-medical treatment were enrolled in this single-arm phase Ⅰ clinical trial.They received anterior-posterior penetrating radiation in a supine or prone position,with a total dose range from 0.5 to 1.5 Gy and a dose weight ratio of 1∶1.The oxygenation status,inflammatory markers,and imaging changes before and after radiotherapy were analyzed,and patients were followed up for acute radiation-induced adverse reactions.Results One week after LDRT,the SaO2/FiO2 or PaO2/FiO2 indices increased in seven patients(87.5％),inflammatory markers such as C-reactive protein(CRP)and interleukin-6(IL-6)decreased in seven patients(87.5％),and chest CT/chest radiographs revealed a significant reduction in the extent of pneumonia involvement in 5 patients(62.5％).No evident acute radiation-related adverse reactions were observed.Conclusions Whole-lung LDRT with a dose range from 0.5 to 1.5 Gy can reduce inflammatory markers,improve clinical symptoms,and promote inflammatory absorption in patients with severe/critical COVID-19 who responded poorly to medical treatment while not inducing acute adverse reactions.
NETL
NSTL
万方数据
